Table 1.
The clinical features and treatment of patients with RA and PsA
| Rheumatoid arthritis | Psoriatic arthritis | p | |
|---|---|---|---|
| n (Female/Male) | 145 (108/37) | 44 (29/15) | NS |
| Age (years) | 53.8±13.1 | 50.1±12 | NS |
| Disease duration (years) | 10.1±8.5 | 7.7±7.9 | NS |
| Methotrexate usage, n (%) | 103 (71.5) | 32 (72.7) | NS |
| Steroid usage, n (%) | 137 (95.1) | 14 (31.8) | <0.001 |
| Anti-TNF-α usage, n (%) | 18 (12.5) | 8 (18.2) | NS |
| Leflunomide usage, n (%) | 16 (11.1) | 2 (4.5) | NS |
| Antimalarial usage, n (%) | 57 (39.6) | 0 | NS |
| Sulfasalazine usage, n (%) | 70 (48.6) | 5 (11.4) | <0.001 |
| Azathiopurine usage, n (%) | 6 (4.2) | 0 | NS |
| DMARD usage, n (%) | 139 (95.9) | 39 (88.6) | NS |
| DAS28 score | 3.45±1.32 | - | - |
| HAQ score | 0.91±0.76 | - | - |
| Sedimentation (mm/hour) | 54.1±34.5 | - | - |
| CRP (mg/dL) | 4.86±8.7 | - | - |
NS: not significant, Anti-TNF-α: anti-tumor necrosis factor-α, DAS: disease activity score, DMARD: disease-modifying anti-malarial drags, HAQ: health assessment questionnaire